Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Sep;35(5):e99.
doi: 10.3802/jgo.2024.35.e99. Epub 2024 Apr 22.

First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial

Xiaohua Wu  1 , Jihong Liu  2 , Ruifang An  3 , Rutie Yin  4 , Yu Zhang  5 , Huaijun Zhou  6 , Aiqin He  7 , Li Wang  8 , Jieqing Zhang  9 , Ziling Liu  10 , Wei Duan  11 , Jianqing Zhu  12 , Ge Lou  13 , Guilin Chen  14 , Ying Cheng  15 , Fengxia Xue  16 , Sonja Nick  17 , Haiyan Wang  18 , Donghang Li  18
Affiliations
Clinical Trial

First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial

Xiaohua Wu et al. J Gynecol Oncol. 2024 Sep.

Abstract

Objective: First-line bevacizumab plus carboplatin and paclitaxel (CP) is approved for stage III/IV ovarian cancer treatment following initial surgical resection, based on global phase III GOG-0218 and ICON7 trials. This study evaluated the efficacy and safety of bevacizumab + CP as first-line ovarian cancer therapy in Chinese patients.

Methods: Patients with newly diagnosed, International Federation of Gynecology and Obstetrics (FIGO) stage III/IV epithelial ovarian, fallopian tube, or primary peritoneal cancer post-primary surgery were randomized 1:1 to receive 6 cycles of CP with bevacizumab/placebo, followed by bevacizumab/placebo maintenance until unacceptable toxicity or disease progression. Primary endpoint was investigator-assessed progression-free survival (PFS). Stratification factors were FIGO stage and debulking status (stage III optimally debulked vs stage III suboptimally debulked vs stage IV) and Eastern Cooperative Oncology Group performance status (0 vs 1 or 2).

Results: Of randomized patients, 51 received bevacizumab + CP and 49 received placebo + CP. Median PFS was 22.6 months with bevacizumab + CP (95% confidence interval [CI]=18.6, not estimable) and 12.3 months (95% CI=9.5, 15.0) with placebo + CP (stratified hazard ratio=0.30; 95% CI=0.17, 0.53). Treatment-related grade 3/4 adverse events occurred in 46 of 49 (94%) patients receiving bevacizumab + CP, and 34 of 50 (68%) receiving placebo + CP.

Conclusion: Bevacizumab + CP showed clinically meaningful improvement in PFS vs placebo + CP, consistent with GOG-0218 results. Safety data were aligned with the known bevacizumab safety profile. These results support first-line bevacizumab + CP therapy in Chinese patients with ovarian cancer.

Trial registration: ClinicalTrials.gov Identifier: NCT03635489.

Keywords: Bevacizumab; Chemotherapy; Chinese; Ovarian Cancer.

PubMed Disclaimer

Conflict of interest statement

W.X., L.J., A.R., Y.R., Z.Y., Z.H., H.A., W.L., Z.J., L.Z., D.W., Z.J., L.G., C.G., C.Y., and X.F. received institute research funding from F. Hoffmann-La Roche Ltd. N.S., W.H., and L.D. are employees of F. Hoffmann-La Roche Ltd. N.S. and W.H. own shares in F. Hoffmann-La Roche Ltd.

Figures

Fig. 1
Fig. 1. PFS per investigator-assessed RECIST v1.1 in the ITT population. (A) Kaplan–Meier curves and (B) forest plots for primary and subgroup analyses.
Bev, bevacizumab; CA, cancer antigen; CI, confidence interval; CP, carboplatin plus paclitaxel; ECOG PS, Eastern Cooperative Oncology Group performance status; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; ITT, intention-to-treat; NE, not estimable; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumours. *All patients were Chinese. †Per electronic case report form, not interactive voice/web response system. ‡Includes those with mixed and mucinous histology.
Fig. 2
Fig. 2. Kaplan–Meier curves for OS in the ITT population.
HRs were measured by unstratified Cox regression. Bev, bevacizumab; CI, confidence interval; CP, carboplatin plus paclitaxel; HR, hazard ratio; ITT, intention-to-treat; NE, not estimable; OS, overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021;134:783–791. - PMC - PubMed
    1. Ebell MH, Culp MB, Radke TJ. A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med. 2016;50:384–394. - PubMed
    1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284–296. - PMC - PubMed
    1. Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol. 2017;28:711–717. - PubMed

Publication types

MeSH terms

Associated data